Arcus Biosciences, Inc. Increase (Decrease) in Other Noncurrent Assets
Arcus Biosciences, Inc. (RCUS) reported Increase (Decrease) in Other Noncurrent Assets of $3.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-05
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was $3.00M.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was $0.00.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was -$6.00M.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent assets for fiscal 2025 was -$5.00M.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent assets for fiscal 2024 was -$22.00M, a 257.14% decline from fiscal 2023.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent assets for fiscal 2023 was $14.00M.
- Arcus Biosciences, Inc. increase (decrease) in other noncurrent assets for fiscal 2022 was -$2.00M, a 166.67% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 3 month as first filed | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 6 month as first filed | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 9 month as first filed | Increase (Decrease) in Other Noncurrent Assets 12 month | Increase (Decrease) in Other Noncurrent Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.00M 10-Q · filed 2026-08-05 | $3.00M derived: sum of 3 quarters · filed 2026-08-05 | -$3.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $3.00M 10-Q · filed 2026-05-05 | $3.00M derived: sum of 2 quarters · filed 2026-05-05 | -$3.00M derived: sum of 3 quarters · filed 2026-05-05 | -$2.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$6.00M derived: sum of 2 quarters · filed 2026-02-25 | -$5.00M derived: sum of 3 quarters · filed 2026-08-05 | -$5.00M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | -$6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$5.00M derived: sum of 2 quarters · filed 2026-08-05 | -$5.00M 10-Q · filed 2025-10-28 | -$11.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.00M 10-Q · filed 2026-08-05 | -$5.00M derived: sum of 3 quarters · filed 2026-08-05 | -$6.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-05 | -$6.00M derived: sum of 2 quarters · filed 2026-05-05 | -$7.00M derived: sum of 3 quarters · filed 2026-05-05 | -$17.00M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$7.00M derived: sum of 2 quarters · filed 2026-02-25 | -$17.00M derived: sum of 3 quarters · filed 2026-02-25 | -$22.00M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$11.00M derived: sum of 2 quarters · filed 2025-10-28 | -$16.00M 10-Q · filed 2025-10-28 | -$14.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | -$10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$15.00M 10-Q · filed 2025-08-06 | -$13.00M derived: sum of 3 quarters · filed 2026-02-25 | -$2.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | -$5.00M 10-Q · filed 2025-05-06 | -$3.00M derived: sum of 2 quarters · filed 2026-02-25 | $8.00M derived: sum of 3 quarters · filed 2026-02-25 | $1.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $13.00M derived: sum of 2 quarters · filed 2026-02-25 | $6.00M derived: sum of 3 quarters · filed 2026-02-25 | $14.00M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.00M derived: sum of 2 quarters · filed 2024-11-06 | $12.00M 10-Q · filed 2024-11-06 | $6.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | -$7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.00M 10-Q · filed 2024-08-08 | -$5.00M derived: sum of 3 quarters · filed 2025-02-25 | $2.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $8.00M 10-Q · filed 2024-05-08 | $2.00M derived: sum of 2 quarters · filed 2025-02-25 | $9.00M derived: sum of 3 quarters · filed 2025-02-25 | -$1.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | -$6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.00M derived: sum of 2 quarters · filed 2025-02-25 | -$9.00M derived: sum of 3 quarters · filed 2025-02-25 | -$2.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$3.00M derived: sum of 2 quarters · filed 2023-11-07 | $4.00M 10-Q · filed 2023-11-07 | $1.64M 10-Q · filed 2022-11-02 | $7.75M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-06-30 | -$10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$3.00M 10-Q · filed 2023-08-07 | $1.44M 10-Q · filed 2022-08-03 | $750.00K derived: sum of 3 quarters · filed 2024-02-21 | $471.00K derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-03-31 | $7.00M 10-Q · filed 2023-05-09 | $1.73M 10-Q · filed 2022-05-09 | $10.75M derived: sum of 2 quarters · filed 2024-02-21 | $10.47M derived: sum of 3 quarters · filed 2024-02-21 | $10.06M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $3.47M derived: sum of 2 quarters · filed 2024-02-21 | $3.06M derived: sum of 3 quarters · filed 2024-02-21 | $3.00M 10-K · filed 2024-02-21 | -$3.32M 10-K · filed 2022-02-23 | |||
| 2021-09-30 | -$279.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$687.00K derived: sum of 2 quarters · filed 2022-11-02 | -$750.00K 10-Q · filed 2022-11-02 | $3.88M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | -$408.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$471.00K 10-Q · filed 2022-08-03 | $4.16M derived: sum of 3 quarters · filed 2023-02-28 | $5.39M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | -$63.00K 10-Q · filed 2022-05-09 | $4.56M derived: sum of 2 quarters · filed 2023-02-28 | $5.80M derived: sum of 3 quarters · filed 2023-02-28 | $5.85M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $4.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $5.87M derived: sum of 2 quarters · filed 2023-02-28 | $5.91M derived: sum of 3 quarters · filed 2023-02-28 | $6.00M 10-K · filed 2023-02-28 | $5.37M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $1.28M derived: sum of 2 quarters · filed 2021-11-08 | $1.37M 10-Q · filed 2021-11-08 | $1.98M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-06-30 | $44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $135.00K 10-Q · filed 2021-08-05 | $744.00K derived: sum of 3 quarters · filed 2022-02-23 | $688.00K derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-03-31 | $91.00K 10-Q · filed 2021-05-05 | $700.00K derived: sum of 2 quarters · filed 2022-02-23 | $644.00K derived: sum of 3 quarters · filed 2022-02-23 | $649.00K derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2019-12-31 | $609.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $553.00K derived: sum of 2 quarters · filed 2022-02-23 | $558.00K derived: sum of 3 quarters · filed 2022-02-23 | $588.00K 10-K · filed 2022-02-23 | ||||
| 2019-09-30 | -$56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$51.00K derived: sum of 2 quarters · filed 2020-11-05 | -$21.00K 10-Q · filed 2020-11-05 | $59.00K derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $35.00K 10-Q · filed 2020-08-06 | $115.00K derived: sum of 3 quarters · filed 2021-02-25 | $115.00K derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $30.00K 10-Q · filed 2020-05-05 | $110.00K derived: sum of 2 quarters · filed 2021-02-25 | $110.00K derived: sum of 3 quarters · filed 2021-02-25 | $110.00K derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $80.00K derived: sum of 2 quarters · filed 2021-02-25 | $80.00K derived: sum of 3 quarters · filed 2021-02-25 | $80.00K 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 | |||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $0.00 10-Q · filed 2019-08-06 | ||||||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-02 | |||||||
| 2017-12-31 | $6.00K 10-K · filed 2019-03-05 | |||||||
| 2016-12-31 | $200.00K 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |